Loading...
Market
Gilead Sciences prioritize Trodelvy market expansion region by end of 2025?
2
Resolution / Starting Odds
Europe • 25%
Asia • 25%
South America • 25%
Africa • 25%
Gilead Sciences press releases and market reports
Story
Gilead Sciences Withdraws Trodelvy Approval for Bladder Cancer
Oct 18, 2024, 04:01 PM
Gilead Sciences announced on Friday that it will voluntarily withdraw the U.S. accelerated approval for its drug Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with locally advanced or metastatic urothelial cancer, specifically in previously treated bladder cancer. The decision follows the results of the TROPiCS-04 study, which failed to meet its primary endpoint of overall survival. Despite this withdrawal, other indications for Trodelvy remain unaffected. The withdrawal comes after consultation with the FDA.
View original story
Similar markets
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
Leading • 25%
Second • 25%
Third • 25%
Lower • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change or decrease • 25%
Europe • 25%
Asia • 25%
North America • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
United States only • 25%
United States and European Union • 25%
United States, European Union, and Japan • 25%
Other combinations or none • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%